Sorrento Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SRNE research report →
About the company
Sorrento Therapeutics, Inc. is a biopharmaceutical company, active in both clinical development and commercial operations, dedicated to creating treatments for a range of serious conditions including cancer, autoimmune disorders, inflammatory diseases, viral infections, and neurodegenerative ailments. The company's operations are divided into two distinct segments: Sorrento Therapeutics and Scilex.
- CEO
- Henry H. Ji
- IPO
- 2007
- Employees
- 949
- HQ
- San Diego, CA, US
Price Chart
- Market Cap
- $303.20K
- P/E
- -0.00
- P/S
- 0.00
- P/B
- -0.01
- EV/EBITDA
- -0.21
- Div Yield
- 0.00%
- Gross Margin
- 46.77%
- Op Margin
- -802.55%
- Net Margin
- -911.60%
- ROE
- -1904.94%
- ROIC
- -286.80%
- Revenue
- $62.84M · 18.78%
- Net Income
- $-572,843,000 · -33.53%
- EPS
- $-1.37 · 6.16%
- Op Income
- $-504,315,000
- FCF YoY
- -5.79%
- 52W High
- $0.10
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 0.11
- Avg Volume
- 515.11K
Get TickerSpark's AI analysis on SRNE
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 17, 23 | Ji Henry | other | 19,500 |
| Mar 17, 23 | Ji Henry | sell | 195 |
| Dec 31, 21 | Janda Kim | other | 0 |
| Dec 21, 22 | Ji Henry | other | 300 |
| Dec 2, 22 | Ji Henry | other | 200 |
| Dec 2, 22 | Ji Henry | other | 2 |
| Dec 21, 22 | Ji Henry | other | 3 |
| Dec 15, 22 | Ji Henry | other | 1,500,000 |
| Sep 7, 22 | Ji Henry | buy | 88,888 |
| Sep 7, 22 | Ji Henry | buy | 759 |
Our SRNE coverage
Recent articles, reports, and earnings notes.
No research on SRNE yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate SRNE report →Similar companies
Peers in the same neighborhood.